Segments

We currently manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of Bio-Reference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the years ended December 31,
(In thousands)	2015			2014			2013
Revenue from services:
Pharmaceutical	$	—		$	—		$	—
Diagnostics	329,599			8,426			10,833
Corporate	140			240			825
	$	329,739		$	8,666		$	11,658
Product revenues:
Pharmaceutical	$	80,146		$	76,983		$	68,161
Diagnostics	—			—			—
Corporate	—			—			—
	$	80,146		$	76,983		$	68,161
Revenue from transfer of intellectual property:
Pharmaceutical	$	81,853		$	5,285		$	15,160
Diagnostics	—			191			1,551
Corporate	—			—			—
	$	81,853		$	5,476		$	16,711
Operating (loss) income:
Pharmaceutical	$	(40,395	)	$	(94,401	)	$	(29,809	)
Diagnostics	(10,294		)	(21,647		)	(22,199		)
Corporate	(46,512		)	(27,725		)	(24,473		)
Less: Operating loss attributable to noncontrolling interests	(1,280		)	(2,042		)	(3,151		)
	$	(98,481	)	$	(145,815	)	$	(79,632	)
Depreciation and amortization:
Pharmaceutical	$	10,245		$	7,936		$	8,234
Diagnostics	31,918			6,894			6,833
Corporate	85			97			149
	$	42,248		$	14,927		$	15,216
Net loss from investment in investees:
Pharmaceutical	$	(7,105	)	$	(3,587	)	$	(11,456	)
Diagnostics	—			—			—
Corporate	—			—			—
	$	(7,105	)	$	(3,587	)	$	(11,456	)
Revenues:
United States	$	344,464		$	14,142		$	28,369
Ireland	78,989			—			—
Chile	29,885			29,154			31,650
Spain	16,622			21,323			18,800
Israel	18,107			20,638			13,252
Mexico	3,671			5,807			4,459
Other	—			61			—
	$	491,738		$	91,125		$	96,530



(In thousands)	December 31, 2015		December 31, 2014
Assets:
Pharmaceutical	$	1,258,011	$	1,064,498
Diagnostics	1,479,841		108,072
Corporate	61,762		95,094
	$	2,799,614	$	1,267,664
Goodwill:
Pharmaceutical	$	251,225	$	173,327
Diagnostics	492,123		50,965
Corporate	—		—
	$	743,348	$	224,292

During the year ended December 31, 2015, revenue recognized under the Pfizer Transaction represented 13% of our total revenue. During the year ended December 31, 2014, one customer of our pharmaceutical segment represented 13% of our total revenue. During the year ended December 31, 2013, no customer represented more than 10% of our total revenue. As of December 31, 2015, one customer represented more than 10% of our accounts receivable balance. As of December 31, 2014 and 2013, no customer represented more than 10% of our accounts receivable balance.

The following table reconciles our Property, plant and equipment, net between U.S. and foreign jurisdictions:



(In thousands)	December 31, 2015		December 31, 2014
PP&E:
U.S.	$	113,307	$	4,286
Foreign	18,491		12,125
Total	$	131,798	$	16,411